ArticleDrug delivery and translational research2025
Fractional erbium-doped yttrium aluminum garnet laser-assisted drug delivery: impact of triamcinolone acetonide formulation on drug permeation.
Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Skin Barrier-Informed Topical and Transdermal Drug Delivery: Excipient-Driven Strategies, Vehicle Transformation, and Translational Challenges.Pharmaceutics · 2026Review
- Radiofrequency Microneedling-Mediated Enhancement in Percutaneous Delivery of Topical Triamcinolone Acetonide: An In Vivo Quantitative Study.Life (Basel, Switzerland) · 2026Article
- Development of Transdermal Drug Delivery Approaches to Combat Diabetes: An Update.Current drug metabolism · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ablative fractional laser-assisted drug delivery has gained attention as a promising method for enhancing dermal drug absorption and improving therapeutic outcomes in dermatological conditions, particularly for hypertrophic and keloid scars. However, despite the growing number of clinical trials and case reports supporting its efficacy, there remains a scarcity of robust evidence on the topical bioavailability and dermato-pharmacokinetics of drugs in human subjects. This study aimed to examine the enhancement of triamcinolone acetonide (TAC) bioavailability following treatment with a fractional Erbium-Doped Yttrium Aluminum Garnet (Er: YAG) laser. Stratum corneum (SC) uptake and transport of TAC from 0.1% TAC cream and 10 mg/mL TAC solution/suspension with and without the laser pre-treatment were determined through tape stripping method for SC collection. TAC therein was quantified by an ultra-performance liquid chromatography coupled with photodiode array (UPLC-PDA) detection. TAC from both formulations without laser assistance was percutaneously absorbed within 6 h and TAC was delivered out from the solution to the SC remarkably higher. When the skin was pre-treated with the laser, permeability of TAC from the solution was escalated by 5 folds. TAC distribution profiles in the SC also confirmed this increased drug uptake, mainly the outer skin layers. On the other hand, amounts of absorbed TAC and their distribution patterns from the cream remained unchanged and low. No adverse events and unbearable pain were observed throughout the experiments. The fractional Er: YAG laser enhanced the dermal absorption of TAC, but this effect was confined to the solution formulation, with no significant improvement seen in the cream. This finding highlights the critical role that drug formulation plays in laser-assisted drug delivery. Moreover, factors such as drug selection, laser type, and optimal laser settings may also impact the efficacy of this approach and require further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.